The U.S. Food and Drug Administration has approved the use of Jardiance 10 mg and 25 mg tables to lower blood sugar along with diet and exercise in children aged 10 years and older with type 2 diabetes, according to drug partners Eli Lilly & Co.
LLY,
and privately held Boehringer Ingelheim. Jardiance, or empagliflozin, is not recommended for use in patients with type 1 diabetes, or to improve glycemic control in patients with type 2 diabetes with an eGFR less than 30 mL/min/1.73 m(2), a reading of kidney function. Type 2 diabetes cases have nearly doubled in young people aged 10 to 19 in the past two decades, raising demand for new treatments. The FDA made its decision based on data from a phase 3 trial dubbed Dinamo. Lilly’s stock has gained 24% in the year to date, while the S&P 500
SPX,
has gained 14%.
